Four Neurology Drug Approvals Reshaping Brain Disease Treatment
From Alzheimer's to Parkinson's, a wave of novel FDA approvals is expanding treatment options for serious neurological conditions.
Summary
The FDA has approved several landmark neurological drugs in 2024–2025 that mark meaningful advances in brain disease treatment. Kisunla (donanemab) became the second amyloid-targeting therapy approved for Alzheimer's disease in 2024, offering a potential disease-modifying option for early-stage patients. Crexont introduced an extended-release formulation of carbidopa/levodopa for more consistent Parkinson's symptom control. IMAVI (nipocalimab) broke new ground in myasthenia gravis by blocking the FcRn receptor, making it effective for both AChR- and MuSK-positive patients aged 12 and older. Adsumi brought a new nasal powder delivery of dihydroergotamine for acute migraine relief. Together, these approvals reflect accelerating momentum in neurology drug development, offering clinicians and patients new tools across a spectrum of debilitating conditions.
Detailed Summary
Neurological diseases represent some of the most challenging and underserved areas in medicine, and recent FDA approvals signal a turning point in how several of these conditions can be managed. Four novel drugs approved between mid-2024 and early 2025 stand out for their clinical significance and potential impact on patient outcomes.
Kisunla (donanemab-azbt), approved July 2024, is an amyloid beta-targeting monoclonal antibody for early symptomatic Alzheimer's disease. It joins lecanemab as only the second disease-modifying therapy for Alzheimer's, with clinical trials showing slowed cognitive decline in patients with confirmed amyloid pathology. This approval reinforces the amyloid hypothesis and expands options for neurologists managing early-stage disease.
Crexont, an extended-release capsule formulation of carbidopa/levodopa, was approved in 2024 for Parkinson's disease. By providing more sustained dopaminergic stimulation, it aims to reduce the motor fluctuations — 'off' episodes and dyskinesia — that plague patients on immediate-release regimens. This is a meaningful quality-of-life improvement for a large patient population.
IMAVI (nipocalimab), approved in early 2025, is the first FcRn receptor blocker approved for generalized myasthenia gravis that covers both AChR-positive and MuSK-positive patients aged 12 and older. By reducing pathogenic IgG antibody levels, it addresses the underlying autoimmune mechanism driving muscle weakness.
Adsumi (dihydroergotamine nasal powder), approved around May 2025, offers a faster-acting, needle-free option for acute migraine attacks, potentially improving adherence and outcomes for patients who struggle with oral medications during active episodes.
Caveats include the fact that long-term safety data for several of these agents remain limited, and access and cost barriers may restrict real-world uptake. Clinicians should weigh individual patient profiles carefully before prescribing.
Key Findings
- Kisunla (donanemab) approved July 2024 as a disease-modifying Alzheimer's therapy targeting amyloid beta in early-stage patients.
- Crexont extended-release carbidopa/levodopa reduces motor fluctuations in Parkinson's patients versus immediate-release formulations.
- IMAVI (nipocalimab) is the first FcRn blocker approved for both AChR- and MuSK-positive myasthenia gravis patients aged 12+.
- Adsumi nasal powder delivers dihydroergotamine rapidly for acute migraine without injection or oral dosing.
- All four approvals address major unmet needs across Alzheimer's, Parkinson's, myasthenia gravis, and migraine.
Methodology
This summary is based on FDA novel drug approval records and secondary sources including clinical trial data submitted for regulatory review. Approval decisions reflect Phase 3 efficacy and safety data reviewed by the FDA. No single head-to-head trial compared these agents.
Study Limitations
This summary is based on the abstract and secondary source data only; full prescribing information and trial publications should be reviewed before clinical application. Long-term safety and real-world effectiveness data are still emerging for most of these approvals. No 2026 FDA neurological approvals were identified in the available data.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.